Biopharma Analyst Chen and Biotech Analysts Kluska & Agrawal, along with Dr. Wajahat Mehal, Professor of Medicine at Yale School of Medicine, discuss new and emerging treatments for Non-Alcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) (relevant companies NVO LLY MRK MDGL AKRO ETNB) on an Analyst/Industry conference call to be held on February 13 at 1 pm. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVO:
- New Environmental / Social Risk for Novo Nordisk – What’s the Latest?
- Unusually active option classes on open January 31st
- Novo Nordisk sees 2024 sales growth of 18-26% at CER
- Novo Nordisk reports 2023 sales up 36% at constant exchange rates to DKK 232.3B
- Novo Nordisk (NYSE:NVO) Reaches New High on Robust Q4 Performance
